A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer

A Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of Gemcitabine Plus LY293111 Compared to Gemcitabine Plus Placebo in Patients With Locally Advanced or Metastatic Pancreatic Cancer

The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine in patients with pancreatic cancer.

Inclusion Criteria:

• Adenocarcinoma of the pancreas that is locally advanced or metastatic and not amenable to resection with curative intent
• Tumor that can be measured by x-ray or scan
• Adequate organ function

Exclusion Criteria:

• Inability to swallow capsules
• Documented brain metastases
• Prior chemotherapy or biological therapy for this disease